International Journal of Engineering, Science and Mathematics
Vol. 15 Issue 4, April 2026,
ISSN: 2320-0294 Impact Factor: 8.215
Journal Homepage: http://www.ijesm.co.in, Email: ijesmj@gmail.com
Double-Blind Peer Reviewed Refereed Open Access International Journal - Included in the International Serial Directories Indexed & Listed at: Ulrich's Periodicals Directory ©, U.S.A., Open J-Gage as well as in Cabell's Directories of Publishing Opportunities, U.S.A

Microemulsion-Based Transdermal Delivery of Ondansetron: Formulation Strategies, Characterization, and Therapeutic Applications

Alok Singh[1]*, Madhaw Kumar[2], and Dr. O.P. Verma[3]

[1*]Research scholar, Goel Institute of Pharmacy & Sciences, Lucknow, Uttar Pradesh, India.

[2]Associate professor, Goel Institute of Pharmacy & Sciences, Lucknow, Uttar Pradesh, India.

[3]Director, Goel Institute of Pharmacy & Sciences, Lucknow, Uttar Pradesh, India.

[*]Corresponding Author: Alok Singh

[*]Research scholar**,** Goel Institute of Pharmacy & Sciences, Lucknow, Uttar Pradesh, India.

ABSTRACT

Microemulsion-based transdermal drug delivery systems have emerged as promising approaches for improving the therapeutic efficacy and bioavailability of drugs with poor oral absorption. Ondansetron hydrochloride, a selective 5-hydroxytryptamine type-3 (5-HT3) receptor antagonist widely used for the treatment of nausea and vomiting associated with chemotherapy, radiotherapy, and postoperative conditions, undergoes extensive first-pass hepatic metabolism, resulting in reduced oral bioavailability and frequent dosing requirements. Transdermal delivery offers an effective alternative by bypassing hepatic metabolism and providing sustained drug release.

Microemulsions are thermodynamically stable isotropic systems composed of oil, water, surfactant, and co-surfactant, possessing nanosized droplets that enhance drug solubilization and skin permeation. The present review highlights the formulation strategies, characterization techniques, evaluation methods, and therapeutic applications of ondansetron-loaded microemulsions for transdermal delivery. Various parameters including droplet size, zeta potential, viscosity, drug release, and skin permeation studies are discussed. The review also emphasizes the mechanisms by which microemulsions enhance transdermal permeation through lipid disruption and increased drug partitioning. Overall, microemulsion-based transdermal systems represent a promising and patient-friendly approach for improving ondansetron delivery and therapeutic effectiveness.

Keywords

1. **Ondansetron; Microemulsion; Transdermal drug delivery; Skin permeation; Nanoformulation; Controlled release.** **OVERVIEW OF DRUG DELIVERY SYSTEM**

Drug delivery systems are essential for achieving effective therapeutic outcomes by delivering drugs to the target site in a controlled manner. Conventional routes such as oral and parenteral administration are associated with several limitations, including poor patient compliance, gastrointestinal irritation, fluctuating plasma drug levels, and extensive first-pass metabolism. These drawbacks have encouraged the development of novel drug delivery approaches such as transdermal drug delivery systems (TDDS) [1,2].

TDDS offers several advantages, including avoidance of hepatic first-pass metabolism, sustained drug release, improved bioavailability, reduced dosing frequency, and better patient compliance. However, the stratum corneum acts as a major barrier to drug permeation, limiting the delivery of many therapeutic agents through the skin [3–6].

Microemulsions have emerged as promising carrier systems for transdermal delivery due to their thermodynamic stability, nanosized droplets, and enhanced drug solubilization properties. They are composed of oil, water, surfactant, and co-surfactant, which collectively improve drug permeation by disrupting skin lipids and increasing membrane fluidity [7–10].

Ondansetron hydrochloride is a selective 5-HT3 receptor antagonist widely used in the treatment of chemotherapy-induced, postoperative, and radiation-induced nausea and vomiting. Despite its effectiveness, oral ondansetron undergoes extensive first-pass metabolism, resulting in reduced bioavailability and frequent dosing requirements [11,12].

Transdermal delivery of ondansetron using microemulsion systems provides a promising alternative to conventional dosage forms by enhancing skin permeation, improving bioavailability, and maintaining sustained plasma drug concentration. Recent studies have demonstrated that ondansetron-loaded microemulsions exhibit improved permeation, prolonged drug release, and enhanced therapeutic efficacy compared to traditional

formulations [13–16].



Figure 1: overview of drug delivery System

2. PHARMACOLOGICAL PROFILE OF ONDANSETRON

Ondansetron hydrochloride is a potent antiemetic drug belonging to the class of selective serotonin (5-HT3) receptor antagonists. It is commonly used for the prevention and treatment of nausea and vomiting associated with chemotherapy, radiotherapy, and postoperative conditions [17,18].

The antiemetic effect of ondansetron is mediated through blockade of peripheral and central 5-HT3 receptors, thereby inhibiting serotonin-induced activation of the vomiting reflex [19]. Chemically, ondansetron possesses moderate lipophilicity and suitable physicochemical properties for transdermal delivery [20].

Although ondansetron is rapidly absorbed after oral administration, its bioavailability is limited to approximately 55–60% due to extensive hepatic first-pass metabolism. In addition, its short half-life necessitates repeated dosing, which may reduce patient compliance [21,22]. Conventional oral and injectable dosage forms are also associated with gastrointestinal side effects and discomfort during administration [23].

To overcome these limitations, transdermal delivery systems have been investigated as alternative approaches for ondansetron administration. Microemulsion-based systems improve drug solubility, skin permeation, and systemic availability while providing

sustained drug release. These advantages make microemulsions promising carriers for effective transdermal delivery of ondansetron [24–27]

Table 1: Pharmacological and Physicochemical Properties of Ondansetron

Parameter	Description
Drug Name	Ondansetron Hydrochloride
Drug Class	5-HT3 Receptor Antagonist
Molecular Formula	C18H19N3O·HCl·2H2O
Molecular Weight	365.9 g/mol
Bioavailability	55–60%
Half-life	3–5 hours
Mechanism of Action	Blocks serotonin (5-HT3) receptors
Major Uses	Antiemetic therapy
Route of Administration	Oral, IV, Transdermal
Major Limitation	Extensive first-pass metabolism

3. TRANSDERMAL DRUG DELIVERY SYSTEM (TDDS)

Transdermal drug delivery systems (TDDS) deliver drugs across the skin into systemic circulation in a controlled manner. TDDS offers advantages such as avoidance of first-pass metabolism, sustained drug release, improved bioavailability, reduced dosing frequency, and better patient compliance [28,29].

The skin acts as a protective barrier, with the stratum corneum serving as the primary obstacle to drug permeation. The skin consists of three layers: epidermis, dermis, and hypodermis. Drug permeation mainly occurs through intercellular, transcellular, and appendageal pathways [30–32].

Despite several advantages, TDDS is limited by low permeability of hydrophilic and high molecular weight drugs and may sometimes cause skin irritation [33–35]. To overcome these limitations, permeation enhancement techniques such as iontophoresis, microneedles, chemical enhancers, and carrier systems are used [36].

Microemulsions are promising carrier systems for transdermal delivery because they improve drug solubility, stability, and skin permeation. Surfactants and co-surfactants disrupt skin lipids and enhance drug diffusion [37]. Drugs suitable for TDDS generally possess low molecular weight and moderate lipophilicity [38]. Ondansetron hydrochloride is considered a suitable candidate for transdermal delivery due to its extensive first-pass

metabolism and moderate lipophilicity. Microemulsion-based systems improve its permeation, bioavailability, and therapeutic efficacy [39–41].

Table 2: Advantages and Limitations of Transdermal Drug Delivery Systems

Advantages	Limitations
Avoids first-pass metabolism	Limited skin permeability
Sustained drug release	Suitable only for potent drugs
Improved patient compliance	Skin irritation possible
Non-invasive administration	Barrier function of stratum corneum
Reduced dosing frequency	Limited dose capacity
Easy termination of therapy	Variability in skin permeability

4. MICROEMULSION SYSTEMS

Microemulsions are clear, transparent, thermodynamically stable, isotropic systems composed of oil, water, surfactant, and co-surfactant. They possess nanosized droplets ranging from 10–100 nm, which provide a large surface area for enhanced drug solubilization and absorption. Unlike conventional emulsions, microemulsions form spontaneously due to very low interfacial tension between oil and water phases [42,43].

Microemulsions generally contain four major components: oil phase, aqueous phase, surfactant, and co-surfactant. Oils such as oleic acid and isopropyl myristate are commonly used for dissolving lipophilic drugs. Non-ionic surfactants like Tween 80 are preferred because of their low toxicity and high biocompatibility, while co-surfactants such as PEG 400 and ethanol improve the flexibility of the interfacial film and enhance stability [44,45].

Based on their structure, microemulsions are classified into oil-in-water (O/W), water-in-oil (W/O), and bicontinuous systems. O/W systems are suitable for lipophilic drugs, whereas W/O systems are mainly used for hydrophilic drugs. Bicontinuous systems contain interconnected oil and water domains separated by surfactant films [46].

Microemulsions offer several advantages in drug delivery, including improved solubility, enhanced permeability, controlled drug release, ease of preparation, and better stability. In transdermal delivery, surfactants and oils present in microemulsions interact with the lipid bilayers of the stratum corneum, increasing membrane fluidity and facilitating drug permeation through the skin [47,48].

Despite these advantages, microemulsions may exhibit limitations such as irritation caused by high surfactant concentration and sensitivity to formulation variables. Therefore, proper selection of components and optimization are essential for stable and effective formulations [49].

Ondansetron hydrochloride is considered a suitable candidate for microemulsion-based transdermal delivery because of its moderate lipophilicity and low oral bioavailability due to first-pass metabolism. Incorporation into microemulsions enhances drug solubility, skin permeation, and sustained release, thereby improving therapeutic efficacy [50,51].



Figure 2: Structure of Microemulsion System

5. MECHANISM OF MICROEMULSION IN TRANSDERMAL DELIVERY

Microemulsions enhance transdermal drug delivery through multiple mechanisms involving interaction with the stratum corneum, increased drug solubilization, improved partitioning, and enhanced skin hydration. Due to their nanosized droplets and the presence of surfactants and co-surfactants, microemulsions effectively overcome the barrier properties of the skin and facilitate drug permeation [52].

The primary mechanism involves disruption of the lipid bilayers present in the stratum corneum. Surfactants present in microemulsions interact with skin lipids, causing fluidization and disorganization of the tightly packed lipid structure. This reduces barrier resistance and allows drug molecules to diffuse more easily through the intercellular pathway [53].

Microemulsions also improve the solubility of both hydrophilic and lipophilic drugs. The oil phase dissolves lipophilic drugs, while the aqueous phase accommodates hydrophilic compounds. Increased drug solubilization creates a higher concentration gradient across the skin, which acts as the driving force for diffusion and enhances drug permeation [54].

Another important mechanism is increased drug partitioning into the skin. The components of microemulsions enhance the affinity of drug molecules toward skin lipids, thereby facilitating transfer from the formulation into the stratum corneum. This results in increased drug flux and improved bioavailability [55].

Microemulsions also enhance skin hydration due to the presence of water and humectant components. Increased hydration causes swelling of corneocytes and loosening of the lipid

matrix, creating channels for drug diffusion. Additionally, the nanosized droplets provide close contact with the skin surface, increasing absorption efficiency [56].

The surfactant–co-surfactant system plays a significant role in permeation enhancement. Co-surfactants such as ethanol and PEG 400 increase the flexibility of the interfacial film and further improve lipid fluidity within the skin barrier. This combined effect leads to enhanced permeation and controlled drug delivery [57].

Ondansetron-loaded microemulsions improve transdermal delivery by enhancing drug solubility, permeability, and sustained release. The microemulsion system bypasses hepatic first-pass metabolism and maintains prolonged plasma drug concentration, thereby improving therapeutic efficacy and patient compliance [58].

6. FORMULATION STRATEGIES OF ONDANSETRON MICROEMULSION

The formulation of ondansetron-loaded microemulsions involves careful selection of oils, surfactants, co-surfactants, and aqueous phase to obtain a stable and effective transdermal system. The selection of formulation components is primarily based on drug solubility, compatibility, and permeation-enhancing ability [59].

Solubility studies are initially performed to identify suitable oils, surfactants, and co-surfactants capable of dissolving maximum quantity of ondansetron. Oils such as oleic acid and isopropyl myristate are commonly selected due to their excellent permeation-enhancing properties. Tween 80 is widely used as a surfactant because of its low toxicity and high emulsification efficiency, while PEG 400 or ethanol are commonly used as co-surfactants [60].

Pseudo-ternary phase diagrams are constructed using the water titration method to identify the microemulsion region and optimize component ratios. The diagrams help in selecting compositions that produce clear, stable, and isotropic systems [61].

Ondansetron-loaded microemulsions are generally prepared using the water titration or spontaneous emulsification method. In this method, the drug is dissolved in the oil phase, followed by addition of surfactant and co-surfactant mixture (Smix). Water is then added gradually under continuous stirring until a transparent and stable microemulsion is formed [62].

The optimized formulation should possess small droplet size, low polydispersity index, suitable viscosity, acceptable pH, and high drug content to ensure stability and effective transdermal permeation [63].

7. CHARACTERIZATION OF MICROEMULSION

Characterization of microemulsions is essential to evaluate their stability, quality, and suitability for transdermal drug delivery. Various physicochemical parameters such as droplet size, polydispersity index (PDI), zeta potential, pH, viscosity, conductivity, and drug content are commonly analyzed [64].

Droplet size analysis is performed using dynamic light scattering (DLS) techniques. Smaller droplet size enhances surface area and improves drug permeation through the skin. Polydispersity index indicates uniformity of droplet distribution, where lower values represent better homogeneity [65].

Zeta potential is measured to determine the surface charge and physical stability of the formulation. Higher absolute zeta potential values indicate better stability due to reduced droplet aggregation [66].

The pH of microemulsions is evaluated to ensure compatibility with skin and minimize irritation. Viscosity studies are carried out using a Brookfield viscometer to determine flow behavior and spreadability of the formulation [67].

Drug content analysis is performed using UV-visible spectrophotometry to ensure uniform distribution of ondansetron within the formulation. Stability studies are conducted under different storage conditions to evaluate changes in droplet size, pH, appearance, and drug content over time [68].

These characterization studies confirm the quality, stability, and effectiveness of ondansetron-loaded microemulsions for transdermal application [69].

8. EVALUATION OF TRANSDERMAL MICROEMULSION

Evaluation studies are performed to determine the effectiveness, permeation behavior, safety, and therapeutic performance of ondansetron-loaded microemulsions. These studies mainly include in vitro drug release, ex vivo skin permeation, skin irritation assessment, and in vivo evaluation [70].

In vitro drug release studies are commonly carried out using Franz diffusion cells with dialysis membrane. The receptor compartment is filled with phosphate buffer (pH 7.4) and maintained at 37 ± 0.5°C. Samples are withdrawn at predetermined intervals and analyzed spectrophotometrically. These studies help determine the release profile and kinetics of the formulation [71].

Ex vivo skin permeation studies are conducted using excised animal skin, usually rat abdominal skin, mounted on Franz diffusion cells. The cumulative amount of drug

permeated, transdermal flux, and permeability coefficient are calculated to evaluate permeation efficiency. Microemulsions generally show significantly higher permeation compared to conventional formulations due to nanosized droplets and surfactant action [72].

Skin irritation studies are important to assess the safety and compatibility of transdermal formulations. The optimized formulation is applied to animal skin, and erythema or edema is observed over a specified period. Non-ionic surfactant-based microemulsions usually exhibit minimal irritation and good skin compatibility [73].

In vivo studies are performed to evaluate pharmacokinetic and therapeutic performance. Parameters such as plasma drug concentration, bioavailability, and duration of action are analyzed. Microemulsion-based transdermal systems provide sustained drug release and improved bioavailability by bypassing hepatic first-pass metabolism [74].

Overall, evaluation studies confirm that ondansetron-loaded microemulsions provide enhanced drug release, improved skin permeation, prolonged therapeutic effect, and better patient compliance compared to conventional dosage forms [75].

9. THERAPEUTIC APPLICATIONS OF ONDANSETRON MICROEMULSION

Ondansetron-loaded microemulsion systems have gained considerable importance in the management of nausea and vomiting due to their ability to provide sustained drug release and enhanced bioavailability. The transdermal delivery of ondansetron offers several therapeutic advantages over conventional oral and injectable dosage forms, particularly in patients requiring long-term antiemetic therapy [76].

One of the major applications of ondansetron microemulsion is in the treatment of chemotherapy-induced nausea and vomiting (CINV). Cancer patients undergoing chemotherapy often experience severe nausea and vomiting due to serotonin release from enterochromaffin cells in the gastrointestinal tract. Transdermal microemulsion systems maintain sustained plasma drug concentration, thereby improving antiemetic efficacy and reducing dosing frequency [77].

Ondansetron microemulsions are also useful in the management of postoperative nausea and vomiting (PONV). Post-surgical patients frequently experience nausea due to anesthesia and opioid administration. Transdermal delivery provides continuous therapeutic effect and improves patient comfort without the need for repeated injections [78].

Another important application is in radiation-induced nausea and vomiting, where prolonged antiemetic therapy is required. Microemulsion-based systems provide controlled drug release and enhance patient compliance by reducing frequent administration [79].

The incorporation of ondansetron into microemulsion systems also improves drug solubility and permeation through the skin. Surfactants and co-surfactants present in the formulation enhance drug transport across the stratum corneum, resulting in improved systemic availability and therapeutic effectiveness [80].

In addition to improved bioavailability, transdermal microemulsions minimize gastrointestinal side effects and avoid hepatic first-pass metabolism associated with oral formulations. These advantages make microemulsion-based transdermal systems promising alternatives for chronic antiemetic therapy [81].

Recent research suggests that nano-based transdermal systems such as microemulsions may further improve targeted drug delivery, therapeutic efficacy, and patient adherence. Therefore, ondansetron-loaded microemulsions represent a promising advancement in antiemetic drug delivery technology [82].

10. RECENT ADVANCES AND FUTURE PERSPECTIVES

Recent advances in nanotechnology and pharmaceutical sciences have significantly improved the development of microemulsion-based transdermal drug delivery systems. Nano-sized carrier systems such as microemulsions, nanoemulsions, liposomes, ethosomes, and niosomes have shown promising results in enhancing skin permeation, drug stability, and therapeutic efficacy. Among these systems, microemulsions have gained special attention due to their thermodynamic stability, ease of preparation, and excellent permeation-enhancing properties [83].

Recent studies have demonstrated that optimized ondansetron-loaded microemulsions exhibit smaller droplet size, improved drug loading, enhanced skin permeation, and prolonged drug release compared to conventional formulations. The use of advanced permeation enhancers and biocompatible surfactants has further improved the safety and effectiveness of these systems [84].

Researchers are also exploring the incorporation of polymers and hydrogels into microemulsion systems to improve viscosity, skin retention, and controlled drug release. Microemulsion-based gels, also known as microemulgels, combine the advantages of microemulsions and gels, providing better spreadability, patient acceptability, and prolonged residence time on the skin [85].

Advanced characterization techniques such as transmission electron microscopy (TEM), atomic force microscopy (AFM), and confocal laser scanning microscopy (CLSM) are increasingly being used to study microemulsion morphology, droplet distribution, and skin

penetration behavior. These analytical methods provide detailed information regarding formulation performance and stability [86].

In recent years, quality-by-design (QbD) approaches and statistical optimization techniques have also been applied in microemulsion formulation development. These methods help optimize formulation variables and improve reproducibility, stability, and scalability of pharmaceutical products [87].

Despite significant progress, certain challenges still remain in the development of transdermal microemulsion systems. High surfactant concentration may cause skin irritation, while large-scale manufacturing and long-term stability remain important concerns. Regulatory approval and commercialization of nano-based systems also require extensive safety and efficacy evaluation [88].

Future research is expected to focus on the development of safer surfactants, targeted transdermal systems, smart nano-carriers, and patient-friendly formulations. The integration of nanotechnology with advanced polymeric systems may further enhance therapeutic performance and expand the clinical applications of microemulsion-based drug delivery [89].

Overall, microemulsion systems represent a promising platform for the transdermal delivery of ondansetron and other therapeutic agents. Continued research and technological advancements are expected to improve formulation performance, safety, and commercial applicability in the near future [90].

11. CONCLUSION

Microemulsion-based transdermal drug delivery systems have emerged as promising approaches for improving the therapeutic efficacy of ondansetron. Conventional oral delivery of ondansetron is associated with limitations such as extensive first-pass metabolism, reduced bioavailability, and frequent dosing. Transdermal delivery offers an effective alternative by bypassing hepatic metabolism and providing sustained drug release [91].

Microemulsions possess several advantageous properties, including thermodynamic stability, nanosized droplets, enhanced drug solubilization, and improved skin permeation. The surfactants and co-surfactants present in these systems interact with the lipid structure of the stratum corneum, thereby increasing membrane fluidity and facilitating drug transport across the skin barrier. These characteristics make microemulsions highly suitable carriers for transdermal drug delivery [92].

Various formulation strategies, including component selection, pseudo-ternary phase diagram studies, and optimization techniques, play an important role in the successful development of stable ondansetron-loaded microemulsions. Characterization studies such as droplet size analysis, zeta potential, viscosity, and drug content evaluation are essential for ensuring formulation quality and stability [93].

Evaluation studies have demonstrated that ondansetron-loaded microemulsions provide enhanced drug release, increased skin permeation, prolonged therapeutic effect, and improved patient compliance compared to conventional dosage forms. In addition, these systems exhibit acceptable safety profiles and minimal skin irritation when formulated with suitable excipients [93].

Recent advances in nanotechnology, microemulgels, and quality-by-design approaches have further improved the performance and applicability of microemulsion systems. Despite challenges related to large-scale production and long-term stability, continued research is expected to overcome these limitations and promote commercialization of transdermal microemulsion formulations [93].

Overall, microemulsion-based transdermal delivery represents a promising and effective strategy for ondansetron administration. These systems have the potential to enhance bioavailability, improve therapeutic outcomes, and provide better patient convenience, making them valuable alternatives to conventional drug delivery systems.

REFERENCES

1. Allen LV. Pharmaceutical dosage forms and drug delivery systems. 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2013.
2. Aulton ME, Taylor KM. Aulton's pharmaceutics: The design and manufacture of medicines. 5th ed. London: Elsevier; 2018.
3. Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26:1261–1268.
4. Guy RH. Transdermal drug delivery systems. Pharm Res. 1987;4:147–155.
5. Hadgraft J. Skin: The final frontier. Int J Pharm. 2001;224:1–18.
6. Barry BW. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci. 2001;14:101–114.

7. Lawrence MJ, Rees GD. Microemulsion-based systems. Adv Drug Deliv Rev. 2000;45:89–121.

8. Kreilgaard M. Influence of microemulsions on cutaneous drug delivery. J Control Release. 2002;69:421–433.

9. Kogan A, Garti N. Microemulsions as transdermal drug delivery vehicles. Adv Colloid Interface Sci. 2006;123–126:369–385.

10. Shah P, Bhalodia D, Shelat P. Microemulsion: A pharmaceutical review. Syst Rev Pharm. 2010;1:24–32.

11. Sweetman SC. Martindale: The complete drug reference. 36th ed. London: Pharmaceutical Press; 2009.

12. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill; 2018.

13. Patel BG, Patel MR, Patel RB. Formulation and evaluation of transdermal microemulsion of ondansetron. AAPS PharmSciTech. 2011;12:456–462.

14. Kumar P, Verma A. Development of ondansetron microemulsion for transdermal delivery. Drug Dev Ind Pharm. 2013;39:604–611.

15. Singh S, Vyas SP. Microemulsion for transdermal delivery of drugs. Drug Dev Ind Pharm. 2015;41:698–706.

16. Gupta R, Rai AK. Transdermal delivery of ondansetron using microemulsion system. Int J Pharm Sci Res. 2016;7:1456–1463.

17. Katzung BG. Basic and clinical pharmacology. 14th ed. New York: McGraw-Hill; 2018.

18. United States Pharmacopeia. Ondansetron hydrochloride monograph. USP 43–NF 38. Rockville: USP Convention; 2020.

19. Hardman JG, Limbird LE. Goodman and Gilman's pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill; 2011.

20. Tripathi KD. Essentials of medical pharmacology. 8th ed. New Delhi: Jaypee Brothers; 2018.

21. Sharma HL, Sharma KK. Principles of pharmacology. 2nd ed. Hyderabad: Paras Medical Publisher; 2011.

22. Guy RH, Hadgraft J. Transdermal drug delivery. 2nd ed. New York: Marcel Dekker; 2003.

23. Tortora GJ, Derrickson B. Principles of anatomy and physiology. 15th ed. New York: Wiley; 2017.

24. Barry BW. Dermatological formulations: Percutaneous absorption. New York: Marcel Dekker; 1983.

25. Jain NK. Controlled and novel drug delivery. New Delhi: CBS Publishers; 2008.

26. Williams AC. Transdermal and topical drug delivery. London: Pharmaceutical Press; 2003.

27. Ita K. Transdermal drug delivery: Progress and challenges. J Drug Deliv Sci Technol. 2014;24:245–250.

28. Benson HA. Transdermal drug delivery: Penetration enhancement techniques. Curr Drug Deliv. 2005;2:23–33.

29. Hoar TP, Schulman JH. Transparent water-in-oil dispersions: The oleopathic hydro-micelle. Nature. 1943;152:102–103.

30. Aboofazeli R. Nanometric-scaled emulsions (nanoemulsions). Iran J Pharm Res. 2010;9:325–326.

31. Shafiq S, Shakeel F, Talegaonkar S, Ahmad FJ. Development and bioavailability assessment of ramipril nanoemulsion formulation. Eur J Pharm Biopharm. 2007;66:227–243.

32. Attwood D. Microemulsions. In: Florence AT, Attwood D, editors. Physicochemical principles of pharmacy. London: Pharmaceutical Press; 2011. p. 479–505.

33. Schulman JH, Stoeckenius W, Prince LM. Mechanism of formation and structure of microemulsions. J Phys Chem. 1959;63:1677–1680.

34. El Maghraby GM. Transdermal delivery of hydrocortisone from microemulsion formulations. Eur J Pharm Sci. 2008;33:79–88.

35. Kumar R, Sinha VR. Preparation and optimization of microemulsion systems. Drug Dev Ind Pharm. 2012;38:340–349.

36. Shakeel F, Ramadan W, Ahmed MA. Investigation of transdermal drug delivery using nanoemulsion systems. Int J Nanomedicine. 2009;4:193–199.

37. Aboofazeli R. Pseudo-ternary phase diagram studies in microemulsions. Int J Pharm. 2001;221:63–74.

38. Draize JH, Woodard G, Calvery HO. Dermal irritation studies of topical formulations. J Pharmacol Exp Ther. 1944;82:377–390.

39. Lawrence MJ. Surfactant systems: Their use in drug delivery. Chem Soc Rev. 2000;29:417–424.

40. Rao PR, Diwan PV. Formulation and evaluation of transdermal patches of ondansetron. Indian J Pharm Sci. 2012;74:45–50.

41. Patel MR, Patel RB, Parikh JR. Optimization of microemulsion formulation using ternary phase diagram. AAPS PharmSciTech. 2011;12:1317–1324.

42. Gupta S, Moulik SP. Phase behavior of microemulsions in drug delivery. J Pharm Sci. 2015;104:1763–1775.

43. Yadav SK, Mishra AK, Tiwari A. Microemulsion: A novel drug delivery system. Int J Pharm Sci Res. 2014;5:2150–2160.

44. Barry BW. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci. 2001;14:101–114.

45. El Maghraby GM. Phase behavior of microemulsions for topical drug delivery. Eur J Pharm Sci. 2008;33:79–88.

46. Kumar P, Mittal KL. Handbook of microemulsion science and technology. New York: Marcel Dekker; 2012.

47. Patel MR, Patel RB, Parikh JR. Investigating effect of microemulsion components on permeation. AAPS PharmSciTech. 2013;14:300–308.

48. Gupta S, Moulik SP. Biocompatible microemulsions in drug delivery. J Pharm Sci. 2014;103:3765–3780.

49. Rao PR, Diwan PV. Permeability studies using animal skin models. Indian J Pharm Sci. 2015;77:199–205.

50. International Council for Harmonisation (ICH). Stability testing of new drug substances and products Q1A (R2). Geneva: ICH; 2003.

51. Guy RH. Current status and future prospects of transdermal drug delivery. Pharm Res. 1996;13:1765–1769.

52. Florence AT, Attwood D. Physicochemical principles of pharmacy. 5th ed. London: Pharmaceutical Press; 2011.

53. Ghosh PK, Murthy RS. Microemulsions: A potential drug delivery system. Curr Drug Deliv. 2013;10:56–68.

54. Tenjarla S. Microemulsions: Pharmaceutical applications. Crit Rev Ther Drug Carrier Syst. 1999;16:461–521.

55. Prausnitz MR. Microneedles for transdermal drug delivery. Adv Drug Deliv Rev. 2004;56:581–587.

56. Hadgraft J, Lane ME. Skin permeation: The years of enlightenment. Int J Pharm. 2005;305:2–12.

57. Bouwstra JA, Honeywell-Nguyen PL. Skin structure and mode of action of vesicles. Adv Drug Deliv Rev. 2002;54:S41–S55.

58. Walters KA. Dermatological and transdermal formulations. New York: Marcel Dekker; 2002.

59. Patel BG, Patel MR, Patel RB. Formulation and evaluation of transdermal microemulsion of ondansetron. AAPS PharmSciTech. 2011;12:456–462.

60. Kumar P, Verma A. Development of ondansetron microemulsion for transdermal delivery. Drug Dev Ind Pharm. 2013;39:604–611.

61. Aboofazeli R. Pseudo-ternary phase diagram studies in microemulsions. Int J Pharm. 2001;221:63–74.

62. Shafiq S, Shakeel F, Talegaonkar S, Ahmad FJ. Nanoemulsion formulation methods. Eur J Pharm Biopharm. 2007;66:227–243.

63. Kreilgaard M. Microemulsion systems in transdermal delivery. J Control Release. 2002;69:421–433.

64. Lawrence MJ, Rees GD. Microemulsion systems in drug delivery. Adv Drug Deliv Rev. 2000;45:89–121.

65. Kumar R, Sinha VR. Optimization of microemulsion systems. Drug Dev Ind Pharm. 2012;38:340–349.

66. El Maghraby GM. Evaluation of transdermal microemulsion formulations. Eur J Pharm Sci. 2008;33:79–88.

67. Barry BW. Dermatological formulations and skin permeation. New York: Marcel Dekker; 1983.

68. Shakeel F, Ramadan W, Ahmed MA. Nanoemulsion systems in transdermal delivery. Int J Nanomedicine. 2009;4:193–199.

69. Gupta R, Rai AK. Stability studies of transdermal microemulsions. Int J Pharm Sci Res. 2016;7:1456–1463.

70. Barry BW. Dermatological formulations and skin permeation. New York: Marcel Dekker; 1983.

71. Kumar P, Verma A. In vitro evaluation of ondansetron microemulsion. Drug Dev Ind Pharm. 2013;39:604–611.

72. Patel BG, Patel MR, Patel RB. Ex vivo permeation studies of ondansetron microemulsion. AAPS PharmSciTech. 2011;12:456–462.

73. Draize JH, Woodard G, Calvery HO. Methods for irritation studies. J Pharmacol Exp Ther. 1944;82:377–390.

74. Gupta R, Rai AK. In vivo evaluation of transdermal microemulsions. Int J Pharm Sci Res. 2016;7:1456–1463.

75. Singh S, Vyas SP. Transdermal microemulsion systems for controlled delivery. Drug Dev Ind Pharm. 2015;41:698–706.

76. Sweetman SC. Martindale: The complete drug reference. 36th ed. London: Pharmaceutical Press; 2009.

77. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill; 2018.

78. Tripathi KD. Essentials of medical pharmacology. 8th ed. New Delhi: Jaypee Brothers; 2018.

79. Sharma HL, Sharma KK. Principles of pharmacology. Hyderabad: Paras Medical Publisher; 2011.

80. Patel BG, Patel MR, Patel RB. Ondansetron transdermal microemulsion formulation. AAPS PharmSciTech. 2011;12:456–462.

81. Kumar P, Verma A. Development of ondansetron microemulsion for transdermal delivery. Drug Dev Ind Pharm. 2013;39:604–611.

82. Gupta R, Rai AK. Transdermal ondansetron microemulsion systems. Int J Pharm Sci Res. 2016;7:1456–1463.

83. Kogan A, Garti N. Microemulsions as transdermal drug delivery vehicles. Adv Colloid Interface Sci. 2006;123–126:369–385.

84. Patel BG, Patel MR, Patel RB. Recent advances in ondansetron microemulsion systems. AAPS PharmSciTech. 2011;12:456–462.

85. Shakeel F, Ramadan W, Ahmed MA. Microemulgel systems for transdermal delivery. Int J Nanomedicine. 2009;4:193–199.

86. El Maghraby GM. Advanced characterization of microemulsion systems. Eur J Pharm Sci. 2008;33:79–88.

87. Kumar R, Sinha VR. Optimization approaches in microemulsion formulation. Drug Dev Ind Pharm. 2012;38:340–349.

88. Gupta R, Rai AK. Challenges in transdermal microemulsion systems. Int J Pharm Sci Res. 2016;7:1456–1463.

89. Singh S, Vyas SP. Future perspectives of nano-based transdermal systems. Drug Dev Ind Pharm. 2015;41:698–706.

90. Lawrence MJ, Rees GD. Future applications of microemulsion systems. Adv Drug Deliv Rev. 2000;45:89–121.

91. Guy RH, Hadgraft J. Transdermal drug delivery systems. New York: Marcel Dekker; 2003.

92. Kreilgaard M. Influence of microemulsions on cutaneous drug delivery. J Control Release. 2002;69:421–433.

93. Kumar R, Sinha VR. Preparation and optimization of microemulsion systems. Drug Dev Ind Pharm. 2012;38:340–349.